Clene will participate in the panel

SALT LAKE CITY, June 27, 2022 (GLOBE NEWSWIRE) — Clene Inc. (CLNN) together with its subsidiaries “Clene” and its wholly-owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced that Rob Etherington, President and Chief from company management, has been invited to participate in the virtual panel “Innovations in ALS – Exploring New Treatments In Development” presented by Maxim Group LLC and hosted by M-Vest at 11 a.m. EDT on Tuesday, June 28. M-Vest members can follow the event live here. On the same link, non-members can register.

Amyotrophic Lateral Sclerosis (ALS) remains a highly debilitating and life-threatening neurological disease despite approved therapies on the market. Current therapies offer benefits to some patients, but there remains a high unmet need for new therapies and disease research. The roundtable, which will focus on current research and development in the area of ​​ALS, will be moderated by Maxim Group Senior Biotechnology Analyst Naz Rahman, CFA, and will feature Mr. Etherington as well as Alon Ben -Noon, co-founder and CEO of NeuroSense Therapeutics.

Focused on advancing new drugs, Clene is currently in late-stage clinical development with its lead drug candidate, CNM-Au8®, as a potential treatment for ALS. The company is awaiting first data in the third quarter from the HEALEY ALS Platform Phase 2/3 registrational trial evaluating CNM-Au8 in patients with ALS. CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. Catalytically active CNM-Au8 nanocrystals drive critical cellular energy-producing responses that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-related stressors. CNM-Au8 is a federally registered trademark of Clene Nanomedicine, Inc.

About Clene

Clene is a clinical-stage biopharmaceutical company whose goal is to revolutionize the treatment of neurodegenerative diseases by targeting energy failures, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit or follow us on Twitter, LinkedInand Facebook.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe port provisions created by such laws. Clene’s forward-looking statements include, but are not limited to, statements regarding our expectations, hopes, beliefs, intentions or strategies or those of our management team regarding our operations In addition, any statement that refers to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. Such forward-looking statements represent our views as of the date of this release. releases and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our perspectives. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date on which they were made, whether as a result of new information, future events or otherwise, unless applicable securities laws require it. Accordingly, forward-looking statements should not be taken as representing our views as of any future date. Due to a number of known and unknown risks and uncertainties, our actual results or performance may differ materially from those expressed or implied by such forward-looking statements. Among the factors that could cause actual results to differ, include our substantial dependence on the successful commercialization of our drug candidates, if approved, in the future; our ability to demonstrate the efficacy and safety of our drug candidates; the clinical results of our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies; our ability to achieve commercial success for our drug candidates, if approved; our ability to obtain additional financing for our operations; the effects of inflation; the effects of personnel and equipment shortages; the possibility that we may be adversely affected by other economic, business and/or competitive factors; and other risks and uncertainties set forth in the “Risk Factors” section of our most recent Annual Report on Form 10-K and all subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the subject matter. These statements are based on information available to us as of the date of this press release, and while we believe this information to be a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be construed as indicating that we have conducted a full investigation or review of all relevant information potentially available. Such statements are inherently uncertain and you are cautioned not to place undue reliance on such statements. All information contained in this press release speaks as of the date of this press release. The information contained in any website referenced herein is not, and should not be considered, a part of or incorporated into this press release.

The information contained in any website referenced herein is not, and should not be considered, a part of or incorporated into this press release.

Contact Investor
Morgan Brown
Financial director
[email protected]

Media Contact
Erica Fiorini, Ph.D., or David Schull
Russo Partners, LLC
[email protected]
[email protected]


Comments are closed.